Chief Executive Officer

Sharon has served as Chief Executive Officer of Neurochase since the company's inception in 2020. In this role she leverages her deep experience in the healthcare and financial growth sectors and provides strategic insights into business development. Sharon is the driving force behind Neurochase's relentless focus on bringing life changing technology to patients suffering from the most debilitating neurological disorders. ​

Prior to her role at Neurochase, Sharon Kane was the CEO of Funding Neuro, a charity focused on supporting research for children with Diffuse Intrinsic Pontine Glioma (DIPG), a rare untreatable aggressive brain tumor with an average survival time of less than 12 months. Sharon has extensive experience leading clinical trials for both neurological disease and neuro-oncology, and over 15 years fundraising experience in the commercial, charity and product development sector.